Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

PhRMA Continues Push For Medicare Part D Redesign In Drug Pricing Legislation

Oct 01 2019

• By Brenda Sandburg

High-cost-medication — PhRMA sees prospects for Medicare Part D redesign in drug pricing legislation

Related Content

Half Of 1st Approved Generics Do Not Launch Due To Part D Formulary Obstacles, AAM Says

Sep 23 2019

House Democrats Launch Price Negotiation Push: Extreme Plan Assures Strong Opposition

Sep 20 2019

Part D Out-Of-Pocket Cap Would Be $2,000 In House Drug Pricing Bill

Sep 20 2019

Point-Of-Sale Rebates May Be Added To US Senate Finance Drug Pricing Bill

Jul 26 2019

Additional Topics

United States Legislation Pricing Debate Reimbursement Policy BioPharmaceutical

More from Legislation

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window